Subscribe
brexit-istock-537519806_andrewlinscott
andrewlinscott / iStockphoto.com
16 July 2018Big Pharma

Brexit plan reassuring for pharma industry, but uncertainties remain: lawyers

While the UK’s pharmaceutical and biotech industries have welcomed the government’s latest White Paper on Brexit, a number of uncertainties remain, according to lawyers.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Parliament votes for UK to stay in EMA
23 July 2018   The UK Parliament has voted in favour of the UK’s continued participation in the European Medicines Agency.
Big Pharma
UK shares Brexit implementation plans for life sciences
6 August 2018   The UK government today published four documents about how Brexit will impact the operations and regulatory status of life sciences companies.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

More on this story

Big Pharma
Parliament votes for UK to stay in EMA
23 July 2018   The UK Parliament has voted in favour of the UK’s continued participation in the European Medicines Agency.
Big Pharma
UK shares Brexit implementation plans for life sciences
6 August 2018   The UK government today published four documents about how Brexit will impact the operations and regulatory status of life sciences companies.

More on this story

Big Pharma
Parliament votes for UK to stay in EMA
23 July 2018   The UK Parliament has voted in favour of the UK’s continued participation in the European Medicines Agency.
Big Pharma
UK shares Brexit implementation plans for life sciences
6 August 2018   The UK government today published four documents about how Brexit will impact the operations and regulatory status of life sciences companies.

More features

Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott
‘A marathon and a sprint at the same time’: How we won $452m damages